Abstract
Biotechnology Law ReportVol. 25, No. 2 TextsGuidance for Industry, Investigators, and Reviewers: Exploratory IND StudiesPublished Online:18 Apr 2006https://doi.org/10.1089/blr.2006.25.167AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetailsCited byA naïve pooled data approach for extrapolation of Phase 0 microdose trials to therapeutic dosing regimens23 November 2022 | Clinical and Translational Science, Vol. 16, No. 2Visualization of Diagnostic and Therapeutic Targets in Glioma With Molecular Imaging30 October 2020 | Frontiers in Immunology, Vol. 11Insight into the Development of PET Radiopharmaceuticals for Oncology21 May 2020 | Cancers, Vol. 12, No. 5Predictive Value of Microdose Pharmacokinetics27 April 2019 | Clinical Pharmacokinetics, Vol. 58, No. 10Ultra-sensitive LC–MS/MS method for the quantification of gemcitabine and its metabolite 2′,2′-difluorodeoxyuridine in human plasma for a microdose clinical trialJournal of Pharmaceutical and Biomedical Analysis, Vol. 151Status and trends in the development of clinical diagnostic agents31 October 2016 | WIREs Nanomedicine and Nanobiotechnology, Vol. 9, No. 4Regulation of Shale Gas Development, Including Hydraulic FracturingSSRN Electronic Journal, Vol. 1 Volume 25Issue 2Apr 2006 InformationCopyright 2006, Mary Ann Liebert, Inc.To cite this article:Guidance for Industry, Investigators, and Reviewers: Exploratory IND Studies.Biotechnology Law Report.Apr 2006.167-174.http://doi.org/10.1089/blr.2006.25.167Published in Volume: 25 Issue 2: April 18, 2006PDF download
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
